Posted by Michael Wonder on 03 Feb 2026
Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, now available in Canada for adult patients with relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukaemia
27 January 2026 - The approval of Jaypirca marks Lilly Canada's first haematology launch in Canada.
Eli Lilly Canada announced today that Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available for use as monotherapy for the treatment of adult patients in Canada with:
- Mantle cell lymphoma relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase inhibitor
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
